SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fourth quarter and full year 2020 financial and operating results after the close of U.S. financial markets on Thursday, February 25, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
Conference call and webcast: | |
Date: | February 25, 2021 |
Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
Passcode: | 5681569 |
Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.
Company Contact: | Investor Contact: |
Mark Wiggins | Brian Ritchie |
Chief Business Officer | LifeSci Advisors LLC |
(858) 251-3492 | 212-915-2578 |
mwiggins@traconpharma.com |
New collaboration delivers 50% off prescription sleep support for new customers who are struggling with…
WILMINGTON, N.C. , June 9, 2025 /PRNewswire/ -- EnrollHere, a next-generation Medicare technology platform, and SunFire,…
Spenser Johnson to Present "Navigating Evolving Water Management Regulations: Ensuring Compliance & Public Safety" Thursday,…
In helping create and scale Oshi as the first nationwide virtual GI clinic, Berry has…
Prescription Discount Program for County Employees in Partnership with BI2 Technologies, LLC FORT EDWARD, N.Y.,…
NEW YORK, June 9, 2025 /PRNewswire/ -- Sage, the first cloud-based operating system built for senior…